Soligenix Inc.
SNGX Healthcare Biotechnology
Soligenix Inc.’s revenue for fiscal 2024 (year ended December 2024) was $119,400.00, down 85.8% from fiscal 2023. In the quarter to June 2026, EPS grew 85.4% and free cash flow grew 37.8%, each against the same quarter a year earlier.
Follow SNGX
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Gross Profit |
+8 more quarters Free account |
— | — | — | — |
R&D Expenses |
1.58 | 2.28 | 1.78 | 0.97 | |
SG&A Expenses |
1.00 | 1.19 | 1.10 | 1.13 | |
Operating Income |
(2.58) | (3.47) | (2.88) | (2.10) | |
Non-operating Income/Expense |
0.05 | 0.07 | 0.06 | 0.11 | |
| (2.53) | (3.40) | (2.82) | (1.99) | ||
Income after Tax |
(2.53) | (2.90) | (2.82) | (1.99) | |
Net Income Common |
(2.53) | (2.90) | (2.82) | (1.99) | |
EPS (Basic) |
(0.58) | 0.24 | (0.28) | (0.12) | |
EPS (Diluted) |
(0.58) | 0.24 | (0.28) | (0.12) | |
Shares (Basic, Weighted) |
4.33 | 5.19 | 10.17 | 15.95 | |
Shares (Diluted, Weighted) |
4.33 | 5.19 | 10.17 | 15.95 | |
EBIT Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBT margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBITDA |
(2.58) | (3.47) | (2.88) | (2.10) | |
EBIT |
(2.58) | (3.47) | (2.88) | (2.10) | |
Income from Continuous Operations |
(2.53) | (2.90) | (2.82) | (1.99) | |
Consolidated Net Income/Loss |
(2.53) | (2.90) | (2.82) | (1.99) | |
EPS (Basic, from Continuous Ops) |
(0.58) | 0.24 | (0.28) | (0.12) | |
EPS (Diluted, from Cont. Ops) |
(0.58) | 0.24 | (0.28) | (0.12) | |
EPS (Basic, Consolidated) |
(0.58) | 0.24 | (0.28) | (0.12) | |
EPS (Diluted, Consolidated) |
(0.58) | 0.24 | (0.28) | (0.12) | |
Shares (Diluted, Average) |
4.31 | — | 10.00 | 16.67 | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% |